Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00774046 · ClinicalTrials.gov registry record · Phase 2
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00774046: Completed Phase 2 study, sponsored by University of Chicago.
NCT00774046 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00774046, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.
Primary Outcome
Complete remission (CR): \<5% bone marrow blasts with recovery of peripheral blood counts; complete cytogenetic remission, the disappearance of any pre-existing cytogenetic abnormality Partial remission (PR): \>5% bone marrow blasts, but less than the pre-treatment blast percentage within the bone marrow Resistant disease (RD): no significant cytoreduction in bone marrow leukemic cells from pre-treatment levels Not evaluable (NE): patients who died during induction chemotherapy or who withdrew f
Interventions
- DRUG Etoposide
- DRUG Mitoxantrone
- DRUG Ara-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2002-12 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
What the finished NCT00774046 record still lists
NCT00774046 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 3 interventions - of which Etoposide is the first listed.
NCT00774046 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00774046 about?
NCT00774046 is a clinical study titled "High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML". The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.
What is the current status of trial NCT00774046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2002-12. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00774046?
The interventions under investigation include: Etoposide (DRUG), Mitoxantrone (DRUG), Ara-C (DRUG).
Who is sponsoring clinical trial NCT00774046?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00774046's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia